risperidone has been researched along with Infusion Site Adverse Event in 1 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 6.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| " Overall, 63 (94%) patients experienced at least one treatment-emergent adverse event (TEAE)." | 2.87 | A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. ( Anta, L; Ayani, I; Gutierro, I; Litman, RE; Llaudó, J; Martínez, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anta, L | 1 |
| Llaudó, J | 1 |
| Ayani, I | 1 |
| Martínez, J | 1 |
| Litman, RE | 1 |
| Gutierro, I | 1 |
1 trial available for risperidone and Infusion Site Adverse Event
| Article | Year |
|---|---|
A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Adm | 2018 |